

|                         |                |
|-------------------------|----------------|
| <b>Reference:</b>       | FOI.17783.25   |
| <b>Subject:</b>         | Ovarian cancer |
| <b>Date of Request:</b> | 11 July 2025   |

**Requested:**

1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?
2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
  - Paclitaxel in combination with a platinum-based compound
  - Platinum-based therapy alone (cisplatin or carboplatin)
  - Bevacizumab in combination with paclitaxel and carboplatin
  - Olaparib
  - Olaparib + Bevacizumab
  - Niraparib
  - Rucaparib
3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part
4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
  - Olaparib
  - Olaparib + Bevacizumab
  - Niraparib
  - Other treatments

**Response:**

1. Hywel Dda University Health Board (UHB) confirms that a total of eleven (11) patients were treated for advanced ovarian cancer, during the period 1 April to 30 June 2025.  
Please note: UHB cancer patients are treated by the UHB and Swansea Bay University Health Board (SBUHB).
2. The UHB provides within the table below, the number of ovarian cancer patients that were treated with the listed medications, during the period 1 April to 30 June 2025.

| Medication                                                 | Number |
|------------------------------------------------------------|--------|
| Paclitaxel in combination with a platinum-based compound   | 15     |
| Platinum-based therapy alone (cisplatin or carboplatin)    | 18     |
| Bevacizumab in combination with paclitaxel and carboplatin | 0      |
| Olaparib                                                   | *      |
| Olaparib + Bevacizumab                                     | *      |
| Niraparib                                                  | *      |
| Rucaparib                                                  | 0      |

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as

there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

3. The UHB confirms that it has not participated in any clinical trials for the treatment of ovarian cancer.
4. The UHB does not hold the requested information. Homologous Recombination Deficiency (HRD) testing is done nationally by the All Wales Medical Genomic Service (AWMGS) hosted by Cardiff and Vale University Health Board (C&VUHB). Further information on the AWMGS can be accessed via the following link:

[AWMGS - Home](#)